Ultreon 3.0 was built to capture and evaluate OCT images, providing real-time guidance during complex PCI procedures.

The FDA is still investigating this issue. For now, the agency recommends considering alternative treatment options when possible.

The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate. Benefits were seen in patients who did and did not lose significant weight as a result of treatment. 

The new Class I recall, which includes more than 1.4 million devices, is related to an issue first announced back in 2024. Updating the software should address the issue going forward, though some patients may still require an early replacement. 

Colleagues from all over the world have shared loving tributes to Braunwald. ESC President Thomas F. Lüscher, MD, called him "the pioneering cardiologist of his time."

The Mosaic Neo mitral bioprosthesis can be implanted through sternotomy, minimally invasive cardiac surgery or robotic access. 

Two separate studies explored the value of treating heart patients with tirzepatide. 

Using a DCB that releases sirolimus over an extended period of time appears to be both safe and effective when treating patients who present with NSTEMI or unstable angina.

Heart Rhythm 2026 Program Chair DJ Lakkireddy, MD, spoke to Cardiovascular Business during the conference about several key EP trends. 

The use of AI to evaluate plaque buildup in CCTA images has been one of cardiology’s biggest ongoing trends. Implementing this software into existing workflows, however, can be a challenge. An upcoming webinar is focused on providing guidance to hospitals and cardiology practices hoping to learn more about this topic. 

SCAI President Dawn Abbott, MD, MSCAI, aims to turn attention toward the long-term sustainability of the interventional cardiology field.